Press Releases
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
Sep 26, 2023
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Sep 08, 2023
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
Sep 06, 2023
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
Aug 23, 2023
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
Aug 23, 2023
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
Aug 17, 2023
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
Aug 15, 2023
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
Jul 21, 2023
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
Jun 13, 2023
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
Jun 05, 2023
Displaying 1 - 10 of 450